KW-3635

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532047

CAS#: N/A

Description: KW-3635 is a thromboxane A2 receptor antagonist.


Chemical Structure

img
KW-3635
CAS# N/A

Theoretical Analysis

MedKoo Cat#: 532047
Name: KW-3635
CAS#: N/A
Chemical Formula: C26H21N2O3-
Exact Mass: 409.16
Molecular Weight: 409.470
Elemental Analysis: C, 76.27; H, 5.17; N, 6.84; O, 11.72

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: KW-3635; KW 3635; KW635.

IUPAC/Chemical Name: (11E)-11-[2-(5,6-dimethylbenzimidazol-1-yl)ethylidene]-6H-benzo[c][1]benzoxepine-2-carboxylate

InChi Key: WZXFXUCKNJCHJG-ZVBGSRNCSA-M

InChi Code: InChI=1S/C26H22N2O3/c1-16-11-23-24(12-17(16)2)28(15-27-23)10-9-21-20-6-4-3-5-19(20)14-31-25-8-7-18(26(29)30)13-22(21)25/h3-9,11-13,15H,10,14H2,1-2H3,(H,29,30)/p-1/b21-9+

SMILES Code: O=C(C1=CC=C(OCC2=CC=CC=C2/C3=C\CN4C5=CC(C)=C(C)C=C5N=C4)C3=C1)[O-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 409.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Higo K, Karasawa A. The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery. Biol Pharm Bull. 1994 Jul;17(7):902-6. PubMed PMID: 8000373.

2: Shirakura S, Higo K, Takeda M, Karasawa A. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol. 1994 Jun;65(2):93-8. PubMed PMID: 7967232.

3: Kawakage M, Sato K, Karasawa A. Protective effect of KW-3635, a specific thromboxane A2-receptor antagonist, on experimental glomerulonephritis in mice. Jpn J Pharmacol. 1994 Jun;65(2):163-6. PubMed PMID: 7967228.

4: Satoh H, Kobayashi T, Higo K, Karasawa A. Protective effects of KW-3635, a thromboxane A2 antagonist, on arachidonic acid-induced transient cerebral ischemia in dogs. Jpn J Pharmacol. 1994 May;65(1):45-50. PubMed PMID: 8089929.

5: Higo K, Karasawa A. Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs. Jpn J Pharmacol. 1993 Dec;63(4):521-3. PubMed PMID: 8121085.

6: Kawakage M, Mizumoto H, Nukui E, Sato S, Karasawa A. Effects of KW-3635, a specific thromboxane A2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice. Jpn J Pharmacol. 1993 Dec;63(4):433-8. PubMed PMID: 8121078.

7: Higo K, Sano J, Karasawa A, Kubo K. The novel thromboxane A2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion. Arch Int Pharmacodyn Ther. 1993 May-Jun;323:32-49. PubMed PMID: 8250642.

8: Kawakage M, Ishihara N, Karasawa A, Kase H. [Effects of KW-3635 on the diuretic action of furosemide in rats]. Nihon Yakurigaku Zasshi. 1993 Jan;101(1):33-8. Japanese. PubMed PMID: 8444379.

9: Miki I, Kishibayashi N, Nonaka H, Ohshima E, Takami H, Obase H, Ishii A. Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64. PubMed PMID: 1434130.

10: Miki I, Ishii A. Characterization of thromboxane A2/prostaglandin H2 receptors in porcine coronary artery--the inhibitory effect of a novel dibenzoxepin derivative, KW-3635. Thromb Haemost. 1992 May 4;67(5):582-4. PubMed PMID: 1387741.

11: Karasawa A, Taylor PA 3rd, Lefer AM. Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock. Eur J Pharmacol. 1990 Jun 21;182(1):1-8. PubMed PMID: 2401310.